Literature DB >> 27372182

[Primary hyperoxaluria: A review].

Hassan Bouzidi1, Ali Majdoub2, Michel Daudon3, Mohamed Fadhel Najjar4.   

Abstract

Primary hyperoxalurias (PH) are inborn errors in the metabolism of glyoxalate and oxalate with recessive autosomal transmission. As a result, an increased endogenous production of oxalate leads to exessive urinary oxalate excretion. PH type 1, the most common form, is due to a deficiency of the peroxisomal enzyme alanine: Glyoxylate aminotransferase (AGT) in the liver. PH type 2 is due to the deficiency of the glyoxylate reductase/hydroxypyruvate réductase, present in the cytosol of hepatocytes and leucocytes. PH type 3 is linked to the gene HOGA1, encoding a mitochondrial enzyme, the 4-hydroxy-2-oxo-glutarate aldolase. Recurrent urolithiaisis and nephrocalcinosis are the markers of the disease. As a result, a progressive dysfunction of the kidneys is commonly observed. At the stage of severe chronic kidney disease, plasma oxalate increase leads to a systemic oxalosis. Diagnostic is often delayed and it based on stone analysis, cristalluria, oxaluria determination and DNA analysis. Early initiation of conservative treatment including high fluid intake and long-term co-administration of inhibitors of calcium oxalate crystallization and pyridoxine, could efficiently prevent end stage renal disease. In end stage renal failure, a combined liver-kidney transplantation corrects the enzyme defect.
Copyright © 2016 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Hyperoxalurie primaire; Lithiase rénale; Nephrocalcinosis; Néphrocalcinose; Oxalate; Primary hyperoxaluria; Urolithiasis

Mesh:

Substances:

Year:  2016        PMID: 27372182     DOI: 10.1016/j.nephro.2016.03.005

Source DB:  PubMed          Journal:  Nephrol Ther        ISSN: 1769-7255            Impact factor:   0.722


  5 in total

1.  Metabolomic and lipidomic characterization of Oxalobacter formigenes strains HC1 and OxWR by UHPLC-HRMS.

Authors:  Casey A Chamberlain; Marguerite Hatch; Timothy J Garrett
Journal:  Anal Bioanal Chem       Date:  2019-02-11       Impact factor: 4.142

Review 2.  Therapeutic RNA-silencing oligonucleotides in metabolic diseases.

Authors:  Algera Goga; Markus Stoffel
Journal:  Nat Rev Drug Discov       Date:  2022-02-24       Impact factor: 84.694

3.  An Angiotensinogen Gene Polymorphism (rs5050) Is Associated with the Risk of Coronary Artery Aneurysm in Southern Chinese Children with Kawasaki Disease.

Authors:  Yunfeng Liu; Lanyan Fu; Lei Pi; Di Che; Yufen Xu; Hao Zheng; Haifeng Long; Lanlan Zeng; Ping Huang; Li Zhang; Tao Yu; Xiaoqiong Gu
Journal:  Dis Markers       Date:  2019-01-03       Impact factor: 3.434

4.  Limited Treatment Options in Primary Hyperoxaluria with Renal Failure.

Authors:  Kyle Geiger; Henry Mroch
Journal:  Case Rep Nephrol Dial       Date:  2020-10-05

Review 5.  Inherited Neuromuscular Disorders: Which Role for Serum Biomarkers?

Authors:  Antonino Lupica; Vincenzo Di Stefano; Andrea Gagliardo; Salvatore Iacono; Antonia Pignolo; Salvatore Ferlisi; Angelo Torrente; Sonia Pagano; Massimo Gangitano; Filippo Brighina
Journal:  Brain Sci       Date:  2021-03-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.